Arterielle Hypertonie – wie behandeln, wann an sekundäre
Transcription
Arterielle Hypertonie – wie behandeln, wann an sekundäre
19.08.2014 Arterielle Hypertonie – wie behandeln, wann an sekundäre Ursachen denken PD Dr. med. Stefano Rimoldi Leiter Hypertonie Kardiologie Inselspital [email protected] Outline 1) Drug therapy 2) Work-up in patients with suspected secondary arterial hypertension. 3) Atherosclerotic renal artery stenosis 4) Catheter-based renal artery denervation 1 19.08.2014 European Guidelines 2013 Mancia et al. J Hypertens and Eur Heart J 2013 Guidelines or … 2 19.08.2014 Reasons for unreached target BP Despite Guidelines only 25% of treated hypertensives reach target blood pressure Patient associated factor: malcompliance Practitioner associated factor: - frequent switching medications - complex treatment regimens - failure to escalate the intensity of therapy despite poorly controlled hypertension Simple Step-Care-Based Algorithm Initial therapy with a low dose ACE/diuretic or ARB/diuretic combination Is blood pressure controlled ? Yes No Continue with current therapy Up-titration of combination therapy successively to the highest dose Yes Continue with current therapy No Add calcium channel blocker and up-titrate Yes Continue with current therapy No Add an α-blocker, β-blocker or spironolactone Feldman RD, Hypertension 2009; 53:646- 3 19.08.2014 Blood Pressure at 6 Months Systolic BP Diastolic BP BP Reduction, mmHg 0 -5 -10 n = 2104 P<0.03 -15 -20 -25 P<0.002 Simple step-care-based algorithm Feldman RD, Hypertension 2009; 53:646- Guideline care Proportion of Patients Achieving Target BP Simple step-carebased algorithm Guidelines care Proportion, % p=0.026 60 50 40 64.7% 52.7% 30 20 10 0 Feldman RD, Hypertension 2009; 53:646- 4 19.08.2014 How should we start drug therapy ? Nice Guidelines 5 19.08.2014 NICE Guidelines A (ACE-H / ARB) Patienten < 55 y C (Ca-Antagonist) Patienten > 55 y A+C A + C + D(iuretikum) A + C + D + R(est) BMJ 2011;343:d4891 doi: 10.1136/bmj.d4891 Take home messages 1) Drug therapy -> A or C; A + C; A + C + D (+R) 2) Work-up in patients with suspected secondary arterial hypertension. 3) Atherosclerotic renal artery stenosis 4) Catheter-based renal artery denervation 6 19.08.2014 Work-up in patients with suspected secondary hypertension Rimoldi SF et al., Eur Heart J 2014 14;35:1245- Suggestive general clinical characteristics Age (i.e. < 30y) in patients without other RF Resistant hypertension (>140/90 mmHg) Severe hypertension (>180/110 mmHg) Sudden BP increase in a previous stable patient Non-dipping/reverse dipping in 24h ABPM Rimoldi SF et al., Eur Heart J 2014 14;35:1245- 7 19.08.2014 Major role of 24h ABPM Exclude white coat effect Confirm therapy resistance Reverse nocturnal dipping Heart rate Low HR, suggestive for therapy adherence (i.e.ß-blocker) Increased HR during nighttime Rimoldi SF et al., Eur Heart J 2014 14;35:1245- Take home messages 1) Drug therapy -> A or C; A + C; A + C + D (+R) 2) Work-up in patients with suspected secondary arterial hypertension -> perform 24h ABPM 3) Atherosclerotic renal artery stenosis 4) Catheter-based renal artery denervation 8 19.08.2014 asymptomatic < 60% RAS without translesional gradient ? Flash pulmonary edema with bilateral RAS CORAL: Stenting and medical therapy for RAS Cooper CJ et a., NEJM 2014;370:13- 9 19.08.2014 CORAL: Stenting and medical therapy for RAS Conclusions: “Renal-artery stenting did not confer a significant benefit with respect to prevention of clinical events when added to comprehensive, multifactorial medical therapy….” Cooper CJ et a., NEJM 2014;370:13- Why ? 10 19.08.2014 CORAL: Baseline characteristics Cooper CJ et a., NEJM 2014;370:13- Relationship between systolic BP and age in patients with RAS after revascularization [mmHg] Systolic BP 200 r=0.79 P<0.001 160 120 80 50 30 70 [years] Age Streeten DH et al., Am J Hypertens 1990;3:360- 11 19.08.2014 Questions Are there predictors for (blood pressure-) effective therapy of a renal artery stenosis ? The “oculo-stenotic reflex” of the interventionalist 30 % 50 % 70 % 90 % “Oculo-stenotic reflex” 12 19.08.2014 Relationship between translesional pressure gradient and quantitative angiographic diameter stenosis Mean PG [mmHg] r=0.43 P=0.12 12 8 4 Stenosis [%] 50 70 Subramanian et al, Catheter Cardiovasc Interv.2005;64:480- Translesional Pressure Gradients to Predict Blood Pressure Response 13 19.08.2014 Ambulatory 24h blood pressure monitoring at baseline and at 3-month follow-up [mmHg] 162±24 143±21 200 P=0.039 150 100 81±12 78±13 Baseline Follow-up p<0.001 50 Baseline Follow-up Systolic BP Diastolic BP Mangiacapra et al, Circ Cardiovasc Interv 2010;3:537- Take home messages 1) Drug therapy -> A or C; A + C; A + C + D (+R) 2) Work-up in patients with suspected secondary arterial hypertension -> perform 24h ABPM 3) Atherosclerotic renal artery stenosis -> don’t trust the “oculostenotic reflex” -> measure translesional gradient 4) Catheter-based renal artery denervation 14 19.08.2014 Renal denervation Renal ischemia or hypoxia RAAS • Vasoconstriction • Atherosclerosis • Sympathetic activtity Thomas G et al. CCJM 2012:79:501- Renal denervation Smithwick R, JAMA 1953;152:1501- 15 19.08.2014 Renal denervation: Expert Consensus ESC 2013 Office systolic BP ≥ 160 mmHg ≥ 3 antihypertensive drugs (inkl. diuretics) Lifestyle modification Exclusion of pseudo-resistance (ABPM) Exclusion of secondary hypertension Preserved renal function (GFR ≥ 45ml/min/1.73) Eligible renal arteries: no polar or accessory arteries, 4 mm diameter, 20 mm length Mahfoud F. et al, Eur Heart J 2013;34:2149- Renal denervation: eligibility n=1209 n=15 (1.2%) Savard S, et al. JACC 2012;60:2422- 16 19.08.2014 Renal denervation: anatomical eligibility Rimoldi SF et al. JACC Cardiovasc Int 2014 Renal denervation: SYMPLICITY HTN-3 Bhatt DL et al. NEJM 2014;370:1393- 17 19.08.2014 Renal denervation: SYMPLICITY HTN-3 Office systolic BP 24h systolic ABPM P= 0.98 P= 0.26 200 RDN Sham 200 120 120 40 40 BL FUP BL FUP RDN BL FUP Sham BL FUP Bhatt DL et al. NEJM 2014;370:1393- Renal denervation: lack of effect on BP 1) Procedure failure. 2) «Pathophysiological failure»: over-activity of renal nerves is not a significant contributor to arterial hypertension. 3) Despite technically successful RDN, no BP lowering because of irreversible vascular changes (arterial stiffening). 18 19.08.2014 Case report: Von Arx R et al, Am J Medicine 2014 in press Case report: Von Arx R et al, Am J Medicine 2014 in press 19 19.08.2014 Arterial stiffness: pulse wave velocity A. carotis A. carotis D A. femoralis A. femoralis T PWV = Distance ( D) / Time delay (T) [m/sec] Case report: arterial stiffness Eur Heart J 2010;31:2338-2350 20 19.08.2014 Take home messages 1) Drug therapy -> A or C; A + C; A + C + D (+R) 2) Work-up in patients with suspected secondary arterial hypertension -> perform 24h ABPM 3) Atherosclerotic renal artery stenosis -> don’t trust the “oculostenotic reflex” -> measure translesional gradient 4) Catheter-based renal artery denervation -> promising technique but...consider -> technical failure -> vascular remodeling PD Dr. med. Stefano Rimoldi Leiter Hypertonie Kardiologie Inselspital [email protected] 21